The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium

Abstract Background Hyponatremia has been associated with poor survival in many solid tumors and more recently found to be of prognostic and predictive value in metastatic renal cell cancer (mRCC) patients treated with immunotherapy. Objective To investigate the influence of baseline hyponatremia in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2014-04, Vol.65 (4), p.723-730
Hauptverfasser:	Schutz, Fabio A.B, Xie, Wanling, Donskov, Frede, Sircar, Monica, McDermott, David F, Rini, Brian I, Agarwal, Neeraj, Pal, Sumanta Kumar, Srinivas, Sandy, Kollmannsberger, Christian, North, Scott A, Wood, Lori A, Vaishampayan, Ulka, Tan, Min-Han, Mackenzie, Mary J, Lee, Jae Lyun, Rha, Sun-Young, Yuasa, Takeshi, Heng, Daniel Y.C, Choueiri, Toni K
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-VEGF Biological and medical sciences Carcinoma, Renal Cell - complications Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - secondary Databases, Factual Female Humans Hyponatremia Hyponatremia - complications Kidney Neoplasms - complications Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Kidneys Male Medical sciences Middle Aged Molecular Targeted Therapy Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Nephrology. Urinary tract diseases Prognosis Prognostic factors Renal cell cancer Retrospective Studies Sodium - blood TOR Serine-Threonine Kinases Treatment Outcome Tumors Tumors of the urinary system Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background Hyponatremia has been associated with poor survival in many solid tumors and more recently found to be of prognostic and predictive value in metastatic renal cell cancer (mRCC) patients treated with immunotherapy. Objective To investigate the influence of baseline hyponatremia in mRCC patients treated with targeted therapy in the International Metastatic Renal Cell Carcinoma Database Consortium. Design, setting, and participants Data on 1661 patients treated with first-line vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) targeted therapy for mRCC were available from 18 cancer centers to study the impact of hyponatremia (serum sodium level
ISSN:	0302-2838 1873-7560
DOI:	10.1016/j.eururo.2013.10.013